Axitinib for renal cell carcinoma
- PMID: 18447599
- DOI: 10.1517/13543784.17.5.741
Axitinib for renal cell carcinoma
Erratum in
- Expert Opin Investig Drugs. 2008 Sep;17(9):1405
Abstract
Background: The approval of sunitinib, sorafenib and temsirolimus has dramatically altered the management of renal cell carcinoma (RCC). Bevacizumab plus IFN may also be added to the therapeutic armamentarium. Axitinib (AG-013736) is an oral and selective tyrosine kinase inhibitor.
Objective: Data supporting the development of axitinib for RCC are reviewed.
Methods: Preclinical and clinical data available for axitinib for RCC are presented.
Results: Axitinib inhibits VEGFR-1, VEGFR-2 and VEGFR-3 with picomolar potencies, and PDGFR-alpha, PDGFR-beta and c-kit with nanomolar potencies. Phase II clinical trials of axitinib in pretreated RCC following sorafenib or cytokine treatment have demonstrated promising activity accompanied by a favorable toxicity profile. Further development of axitinib for RCC is warranted.
Similar articles
-
Axitinib for the management of metastatic renal cell carcinoma.Drugs R D. 2011;11(2):113-26. doi: 10.2165/11591240-000000000-00000. Drugs R D. 2011. PMID: 21679004 Free PMC article. Review.
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Lancet. 2011. PMID: 22056247 Clinical Trial.
-
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?Expert Rev Anticancer Ther. 2010 Oct;10(10):1545-57. doi: 10.1586/era.10.134. Expert Rev Anticancer Ther. 2010. PMID: 20942625 Review.
-
Axitinib (Inlyta) for advanced renal cell carcinoma.Med Lett Drugs Ther. 2012 Jun 11;54(1392):47-8. Med Lett Drugs Ther. 2012. PMID: 22683928 No abstract available.
-
Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Expert Opin Drug Discov. 2015;10(8):925-35. doi: 10.1517/17460441.2015.1045411. Epub 2015 Jun 3. Expert Opin Drug Discov. 2015. PMID: 26039031 Review.
Cited by
-
Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy.Cancer Res Treat. 2023 Apr;55(2):643-651. doi: 10.4143/crt.2022.883. Epub 2022 Nov 28. Cancer Res Treat. 2023. PMID: 36470258 Free PMC article.
-
Rational Drug Discovery for Isoxazole Based VEGFR2 Inhibition.Curr Drug Discov Technol. 2025;22(2):e240524230316. doi: 10.2174/0115701638296906240522072628. Curr Drug Discov Technol. 2025. PMID: 38798213
-
A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma.Mol Clin Oncol. 2020 Mar;12(3):284-289. doi: 10.3892/mco.2020.1978. Epub 2020 Jan 16. Mol Clin Oncol. 2020. PMID: 32064108 Free PMC article.
-
Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.BMC Cancer. 2016 Mar 17;16:232. doi: 10.1186/s12885-016-2272-7. BMC Cancer. 2016. PMID: 26983443 Free PMC article.
-
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.Mol Cancer Ther. 2008 Dec;7(12):3670-84. doi: 10.1158/1535-7163.MCT-08-0715. Mol Cancer Ther. 2008. PMID: 19074844 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
